Promotions For Black-Box Drugs Aren’t Specific Enforcement Targets, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advertising enforcement does not preference black-box drugs despite risk-based approach prioritizing products with significant risks; nor are drugs with small patient populations exempt from risk-based approach.